PIK3CA mutation, reduced AKT serine 473 phosphorylation, and increased ERα serine 167 phosphorylation are positive prognostic indicators in postmenopausal estrogen receptor-positive early breast cancer

Abstract P4-08-07: PIK3CA mutation, reduced AKT serine 473 phosphorylation, and increased ERα serine 167 phosphorylation are positive prognostic indicators in postmenopausal estrogen receptor-positive, HER2-negative early breast cancer

10.1158/1538-7445.sabcs17-p4-08-07 ◽

2018 ◽

Author(s):

N Ishida ◽

Y Hatanaka ◽

M Baba ◽

K Hagio ◽

H Okada ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Early Breast Cancer ◽

Pik3ca Mutation ◽

Prognostic Indicators ◽

Identifying oncogenic drivers associated with increased risk of late distant recurrence in postmenopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study

Annals of Oncology ◽

10.1016/j.annonc.2020.06.024 ◽

2020 ◽

Vol 31 (10) ◽

pp. 1359-1365 ◽

Cited By ~ 1

Author(s):

S.J. Luen ◽

R. Asher ◽

C.K. Lee ◽

P. Savas ◽

R. Kammler ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Early Breast Cancer ◽

Distant Recurrence ◽

Increased Risk ◽

Faculty Opinions recommendation of Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.734565867.793581155 ◽

2020 ◽

Author(s):

David Potter

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Neoadjuvant Therapy ◽

Early Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Randomized Phase Ii ◽

The clinical usefulness of the CTS5 in the prediction of late distant recurrence in postmenopausal women with estrogen receptor-positive early breast cancer

Breast Cancer ◽

10.1007/s12282-020-01130-y ◽

2020 ◽

Author(s):

Wakako Tajiri ◽

Hideki Ijichi ◽

Katsumi Takizawa ◽

Yumiko Koi ◽

Takanobu Masuda ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Postmenopausal Women ◽

Early Breast Cancer ◽

Distant Recurrence ◽

Clinical Usefulness ◽

Neoadjuvant letrozole for postmenopausal estrogen receptor-positive, HER2-negative breast cancer patients, a study from the Danish Breast Cancer Cooperative Group (DBCG)

Acta Oncologica ◽

10.1080/0284186x.2017.1401228 ◽

2017 ◽

Vol 57 (1) ◽

pp. 31-37 ◽

Cited By ~ 4

Author(s):

Signe Korsgaard Skriver ◽

Anne-Vibeke Laenkholm ◽

Birgitte Bruun Rasmussen ◽

Jürgen Handler ◽

Bo Grundtmann ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Cancer Patients ◽

Cooperative Group ◽

Breast Cancer Patients ◽

Distribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive, HER2-negative early breast cancer patients

Oncotarget ◽

10.18632/oncotarget.16313 ◽

2017 ◽

Vol 8 (24) ◽

pp. 38706-38716 ◽

Cited By ~ 11

Author(s):

Jiayi Wu ◽

Yan Fang ◽

Lin Lin ◽

Xiaochun Fei ◽

Weiqi Gao ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Cancer Patients ◽

Early Breast Cancer ◽

Recurrence Score ◽

Distribution Patterns ◽

Breast Cancer Patients ◽

The efficacy of sequential second-line endocrine therapies (ETs) in postmenopausal estrogen receptor-positive and HER2-negative metastatic breast cancer patients with lower sensitivity to initial ETs

Breast Cancer ◽

10.1007/s12282-020-01095-y ◽

2020 ◽

Vol 27 (5) ◽

pp. 973-981

Author(s):

Takayuki Iwamoto ◽

Tomomi Fujisawa ◽

Tadahiko Shien ◽

Kazuhiro Araki ◽

Kentaro Sakamaki ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Metastatic Breast Cancer ◽

Cancer Patients ◽

Metastatic Breast ◽

Lower Sensitivity ◽

Second Line ◽

Breast Cancer Patients ◽

Economic Assessment of Routine Oncotype DX Testing of Estrogen Receptor Positive (ER+) Early Breast Cancer (EBC) Patients with Grade 2 Tumours in Czech Republic

Value in Health ◽

10.1016/j.jval.2016.09.2140 ◽

2016 ◽

Vol 19 (7) ◽

pp. A720 ◽

Cited By ~ 1

Author(s):

K Hejduk ◽

K Petrakova ◽

L Petruzelka ◽

Z Bielcikova ◽

I Kolarova ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Czech Republic ◽

Early Breast Cancer ◽

Economic Assessment ◽

Oncotype Dx ◽

Abstract P5-14-01: A meta-analysis of clinical benefit rates for fulvestrant 500 mg versus alternative therapies for treatment of postmenopausal, estrogen receptor-positive advanced breast cancer

10.1158/1538-7445.sabcs15-p5-14-01 ◽

2016 ◽

Author(s):

JFR Robertson ◽

J Zefei ◽

A Di Leo ◽

S Ohno ◽

KI Pritchard ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Advanced Breast Cancer ◽

Clinical Benefit ◽

Meta Analysis ◽

Alternative Therapies ◽

Advanced Breast ◽

Abstract P3-08-55: Factors associated with prolonged post-recurrence survival in patients with postmenopausal estrogen receptor-positive breast cancer taking fulvestrant: A follow-up data of the JBCRG-C06 Safari study factors associated with prolonged post-recurrence survival in patients with postmenopausal estrogen receptor-positive breast cancer taking fulvestrant: A follow-up data of the JBCRG-C06 Safari study

10.1158/1538-7445.sabcs19-p3-08-55 ◽

2020 ◽

Author(s):

Kenjiro Aogi ◽

Hidetoshi Kawaguchi ◽

Norikazu Masuda ◽

Takahiro Nakayama ◽

Keisei Anan ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Factors Associated ◽

Postmenopausal Estrogen ◽

Positive Breast Cancer